Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Cisplatin/Alimta Receives FDA Approval for First Line Advanced NSCLC, Non-Squamous Only
Author
Howard (Jack) West, MD

Yesterday, as described in a press release, the FDA approved the regimen of cisplatin and alimta as a first line therapy for advanced NSCLC, based on the positive results from a trial called "JMDB" by the sponsor company (Eli Lilly). I described the highlights in a prior post, also recently published (abstract here). It compared cisplatin/gemcitabine to cisplatin/alimta (pemetrexed) in 1725 patients with previously untreated advanced NSCLC and found that the overall efficacy was the same between the two regimens, with a little more favorable side effect profile on the alimta arm. That wasn't the interesting part.

The part that generated interest within the lung cancer community was the fact that the different main subtypes of NSCLC (tumor histology) did better with one chemo regimen or the other. Patients with squamous NSCLC did better on cisplatin/gemcitabine, while the patients with adenocarcinoma or large cell NSCLC did better on cisplatin/alimta, as shown in both the survival curves and the table below:

JMDB OS (click to enlarge)

JMDB histology table

Based on these results, the FDA approved the combination of cisplatin and alimta as a first line therapy, for patients with non-squamous NSCLC only. In addition, based on these findings and other work (see prior post), the FDA also amended the current approval of alimta as a second line therapy to only include treatment for patients with non-squamous NSCLC.

This is particularly important because up until very recently, there was no reason to suspect that alimta wasn't useful for the broader population of patients with advanced NSCLC, squamous and non-squamous alike. But I've done a series of lectures for general oncologists over the last couple of months, preceded by a series of case-based questions about how they would manage certain clinical situations, and it's been clear that only a minority of practicing oncologists are aware of the now compelling evidence that alimta is simply not an effective treatment for squamous NSCLC (it didn't beat placebo in a recent trial), while its activity is particularly pronounced for non-squamous NSCLC, where all of its previously noted activity appears to be concentrated.

The other important factor is that, along with the histology-specific results with avastin, there's more evidence that we need to tailor our treatments for patients by keeping their NSCLC subtype in mind. This means that we need to get enough tumor tissue at the time of biopsy to clarify the subtype. We are entering an era where our treatments for lung cancer now need to be individualized.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on